Integrated PET/CT in non-small cell lung cancer staging—Clinical and pathological agreement
AP Vaz, G Fernandes, CS Moura, P Bastos… - Revista Portuguesa de …, 2012 - Elsevier
Abstract Introduction Integrated PET/CT has become a fundamental tool in the preoperative
assessment of non-small cell lung cancer (NSCLC) providing useful anatomical and …
assessment of non-small cell lung cancer (NSCLC) providing useful anatomical and …
[HTML][HTML] Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer
K Shimizu, R Okita, S Saisho, T Yukawa… - Annals of Nuclear …, 2015 - Springer
Objective The maximal standardized uptake value (SUVmax) of pulmonary lesions on dual-
time-point (DTP) fluorodeoxyglucose positron emission tomography (FDG-PET) has been …
time-point (DTP) fluorodeoxyglucose positron emission tomography (FDG-PET) has been …
FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy
R Kremer, Y Peysakhovich, LF Dan, L Guralnik… - Annals of nuclear …, 2016 - Springer
Objective Neoadjuvant chemoradiotherapy (CMRT) is the most effective treatment of stage III
non-small-cell lung cancer (NSCLC). The present study aimed at assessing FDG PET/CT for …
non-small-cell lung cancer (NSCLC). The present study aimed at assessing FDG PET/CT for …
Accuracy of fluorodeoxyglucose-positron emission tomography within the clinical practice of the American College of Surgeons Oncology Group Z4031 trial to …
EL Grogan, SA Deppen, KV Ballman… - The Annals of Thoracic …, 2014 - Elsevier
Background Fluorodeoxyglucose-positron emission tomography (FDG-PET) is
recommended for diagnosis and staging of non-small cell lung cancer (NSCLC). Meta …
recommended for diagnosis and staging of non-small cell lung cancer (NSCLC). Meta …
Risk factors for predicting occult lymph node metastasis in patients with clinical stage I non-small cell lung cancer staged by integrated fluorodeoxyglucose positron …
K Kaseda, K Asakura, A Kazama, Y Ozawa - World journal of surgery, 2016 - Springer
Background Lymph nodes in patients with non-small cell lung cancer (NSCLC) are often
staged using integrated 18F-fluorodeoxyglucose positron emission tomography/computed …
staged using integrated 18F-fluorodeoxyglucose positron emission tomography/computed …
The value of [18F] fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined …
CJ Hoekstra, SG Stroobants, OS Hoekstra… - Lung cancer, 2003 - Elsevier
Combined modality treatment (CMT) for patients with stage IIIA-N2 non-small cell lung
cancer (NSCLC) is at present studied extensively. To select patients with truly stage IIIA-N2 …
cancer (NSCLC) is at present studied extensively. To select patients with truly stage IIIA-N2 …
[HTML][HTML] Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection
S Harmon, CW Seder, S Chen, A Traynor… - Journal of Thoracic …, 2019 - ncbi.nlm.nih.gov
Background Preoperative identification of non-small cell lung cancer (NSCLC) patients at
risk for disease recurrence has proven unreliable. The extraction of quantitative metrics from …
risk for disease recurrence has proven unreliable. The extraction of quantitative metrics from …
[PDF][PDF] Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer
Purpose Positron emission tomography (PET) is a costly new technology with potential to
improve preoperative evaluation for patients with non–small-cell lung cancer (NSCLC) …
improve preoperative evaluation for patients with non–small-cell lung cancer (NSCLC) …
Prognostic value of computed tomography and/or 18F-fluorodeoxyglucose positron emission tomography radiomics features in locally advanced non-small cell lung …
A Moran, Y Wang, BA Dyer, SSF Yip, ME Daly… - Clinical lung cancer, 2021 - Elsevier
Introduction We investigated whether adding computed tomography (CT) and/or 18 F-
fluorodeoxyglucose (18 F-FDG) PET radiomics features to conventional prognostic factors …
fluorodeoxyglucose (18 F-FDG) PET radiomics features to conventional prognostic factors …
[HTML][HTML] FDG PET/CT overcomes discordance between clinical and pathologic TNM classification of small-size primary lung cancer: influence on postoperative …
Introduction We aimed to determine the concordance between the clinical stage (c-stage)
and pathologic stage (p-stage) for patients with small-size lung cancer. Additionally we …
and pathologic stage (p-stage) for patients with small-size lung cancer. Additionally we …